USP28 deletion and small molecule inhibition destabilises c-MYC and elicits regression of squamous cell lung carcinoma
- The Francis Crick Institute, United Kingdom
- University of Oxford, United Kingdom
- CRUK Therapeutic Discovery Laboratories, United Kingdom
- Forma Therapeutics, United States
- Novartis Institutes of BioMedical Research, United States
- FORMA Therapeutics, United States
- University College London, United Kingdom
- Francis Crick Institute, United Kingdom
- Max Planck Institut, Dortmund, Germany
- Walter and Eliza Hall Institute of Medical Research, Australia
- Liverpool University, United Kingdom
Abstract
Lung squamous cell carcinoma (LSCC) is a considerable global health burden, with an incidence of over 600,000 cases per year. Treatment options are limited, and patient 5-year survival rate is less than 5%. The ubiquitin specific protease 28 (USP28) has been implicated in tumorigenesis through its stabilization of the oncoproteins c-MYC, c-JUN and Dp63. Here, we show that genetic inactivation of Usp28 induced regression of established murine LSCC lung tumours. We developed a small molecule that inhibits USP28 activity in the low nanomole range. While displaying cross-reactivity against the closest homologue USP25, this inhibitor showed a high degree of selectivity over other deubiquitinases. USP28 inhibitor treatment resulted in a dramatic decrease in c-MYC, c-JUN and Dp63 proteins levels and consequently induced substantial regression of autochthonous murine LSCC tumors and human LSCC xenografts, thereby phenocopying the effect observed by genetic deletion. Thus, USP28 may represent a promising therapeutic target for the treatment of squamous cell lung carcinoma.
Data availability
For all figures with graphs we provide source data files in the Supplemental Information section. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with an internal ID of PXD469830.
Article and author information
Author details
Benedikt M Kessler
Funding
Forma Therapeutics (2013-2019)
- E Josue Ruiz
- Adan Pinto-Fernandez
- Andrew P Turnbull
- Linxiang Lan
- Thomas M Charlton
- Hannah C Scott
- Andreas Damianou
- George Vere
- Eva M Riising
- Clive Da Costa
- Wojciech W Krajewski
- David Guerin
- Jeffrey D Kearns
- Stephanos Ioannidis
- Marie Katz
- Crystal McKinnon
- Jonathan O'Connell
- Natalia Moncaut
- Ian Rosewell
- Emma Nye
- Neil Jones
- Claire Heride
- Malte Gersch
- Min Wu
- Christopher J Dinsmore
- Tim R Hammonds
- Sunkyu Kim
- David Komander
- Sylvie Urbe
- Michael J Clague
- Benedikt M Kessler
- Axel Behrens
Cancer Research UK Manchester Centre (FC001039)
- Axel Behrens
Medical Research Council (FC001039)
- Axel Behrens
Wellcome Trust (FC001039)
- Axel Behrens
Wellcome Trust (097813/Z/11/Z)
- Benedikt M Kessler
Engineering and Physical Sciences Research Council (EP/N034295/1)
- Benedikt M Kessler
John Fell Fund, University of Oxford (133/075)
- Benedikt M Kessler
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animal experiments were approved by the Francis Crick Institute Animal Ethics Committee and conformed to UK Home Office regulations under the Animals (Scientific Procedures) Act 1986 including Amendment Regulations 2012.
Copyright
© 2021, Ruiz et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,939
- views
-
- 586
- downloads
-
- 28
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
USP28 deletion and small molecule inhibition destabilises c-MYC and elicits regression of squamous cell lung carcinoma
eLife 10:e71596.
https://doi.org/10.7554/eLife.71596
Further reading
-
- Biochemistry and Chemical Biology
- Stem Cells and Regenerative Medicine
Human induced pluripotent stem cells (hiPSCs) have great potential to be used as alternatives to embryonic stem cells (hESCs) in regenerative medicine and disease modelling. In this study, we characterise the proteomes of multiple hiPSC and hESC lines derived from independent donors and find that while they express a near-identical set of proteins, they show consistent quantitative differences in the abundance of a subset of proteins. hiPSCs have increased total protein content, while maintaining a comparable cell cycle profile to hESCs, with increased abundance of cytoplasmic and mitochondrial proteins required to sustain high growth rates, including nutrient transporters and metabolic proteins. Prominent changes detected in proteins involved in mitochondrial metabolism correlated with enhanced mitochondrial potential, shown using high-resolution respirometry. hiPSCs also produced higher levels of secreted proteins, including growth factors and proteins involved in the inhibition of the immune system. The data indicate that reprogramming of fibroblasts to hiPSCs produces important differences in cytoplasmic and mitochondrial proteins compared to hESCs, with consequences affecting growth and metabolism. This study improves our understanding of the molecular differences between hiPSCs and hESCs, with implications for potential risks and benefits for their use in future disease modelling and therapeutic applications.
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
Dynamic conformational and structural changes in proteins and protein complexes play a central and ubiquitous role in the regulation of protein function, yet it is very challenging to study these changes, especially for large protein complexes, under physiological conditions. Here, we introduce a novel isobaric crosslinker, Qlinker, for studying conformational and structural changes in proteins and protein complexes using quantitative crosslinking mass spectrometry. Qlinkers are small and simple, amine-reactive molecules with an optimal extended distance of ~10 Å, which use MS2 reporter ions for relative quantification of Qlinker-modified peptides derived from different samples. We synthesized the 2-plex Q2linker and showed that the Q2linker can provide quantitative crosslinking data that pinpoints key conformational and structural changes in biosensors, binary and ternary complexes composed of the general transcription factors TBP, TFIIA, and TFIIB, and RNA polymerase II complexes.
